At present, availability of fully characterized, consistent and validated starting materials has posed significant limitations in this field, but new, higher throughput processes are gaining momentum, lowering material costs and increasing scalability.​ Historically, cell and gene therapies have been used to cure rare and ultra-rare diseases. With new efficiencies on the horizon, what does this mean for the future of these therapies and their potential to treat a wider patient population?

​In this webinar, our panel of experts will discuss:

• Are autologous therapies here to stay?
• Are allogeneic therapies the future?
• The unlimited scope of gene editing technologies